Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
Liqin YaoGang JiaChangquan LingWenxue MaPublished in: Current oncology (Toronto, Ont.) (2022)
Neoadjuvant chemotherapy (NACT) was developed with the aims of shrinking tumors or stopping cancer cells from spreading before surgery. Unfortunately, not all breast cancer patients will benefit from NACT, and thus, patients must weigh the risks and benefits of treatment prior to the initiation of therapy. Currently, the data for predicting the efficacy of NACT is limited. Molecular testing, such as Oncotype DX, MammaPrint, and Curebest 95GC, have been developed to assist which breast cancer patients will benefit from the treatment. Patients with an increased level of Human Leukocyte Antigen-DR isotype, tumor-infiltrating lymphocytes, Fizzy-related protein homolog, and a decreased level of tumor-associated macrophages appear to benefit most from NACT.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- lymph node
- end stage renal disease
- endothelial cells
- newly diagnosed
- chronic kidney disease
- rectal cancer
- peripheral blood
- papillary thyroid
- stem cells
- sentinel lymph node
- coronary artery disease
- coronary artery bypass
- peritoneal dialysis
- mesenchymal stem cells
- high resolution
- atrial fibrillation
- editorial comment